ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NGEN / insiders
DERM (16) PDSB (46) CUE (29) MENS (33) ⌘ Pro Terminal →

NervGen Pharma Corp. (NGEN) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.35 -1.46% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.34

NervGen Pharma Corp. (NGEN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $147.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.35 (-1.46% 1D, market cap $147.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #370 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NGEN compare to DERM and PDSB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DERM (Journey Medical Corporation) holds a E grade (16/100 RQD, P/E N/A, ROIC -19.5%, cap $145.9M) and PDSB (PDS Biotechnology Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NGEN?
▼

For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.34 (-0.45%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
$7 Bull$1 Base$1 Bear
📬 FREE NGEN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NGEN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY NGEN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$1.63-5.5% Next Q
Q2 (-2Q)
50
Grade C-$1.54-3.9% Next Q
Q3 (-1Q)
48
Grade D$1.48-8.8% Next Q
Current
45
Grade D$1.35-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NGEN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NGEN currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.87) and Max Pain ($1.42) forces dealer call-delta covering toward $6.62.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NGEN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NGEN Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NGEN)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NGEN. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NGEN)

  • ✓Walkthrough of NGEN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.11%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.44H $1.44L $1.35C $1.35VOL 546.9K
RES: $2.45SUP: $1.34SMA50: $1.87SMA200: $2.80
$4.19$3.42$2.65$1.88$1.11RES $2.45SUP $1.34$1.352026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NGEN Butterfly Map → + Track NGEN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NGEN)

Health Care Rank #370 of 1016 ⚔️ DERM vs NGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NGEN vs. DERM, PDSB, CUE, MENS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NervGen Pharma Corp. (NGEN) ranks #370 by composite RQD confidence (45/100, grade D) and #607 by equity capitalization ($147.4M). Within this direct 5-issuer industry benchmark cohort, NGEN leads on earnings valuation at N/A trailing P/E, while DERM leads on capital efficiency and profitability with -19.5% ROIC and 65.8% gross margin. PDSB currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NGEN at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NGEN ACTIVE
NervGen Pharma Corp.
D 45/100 — — — -1.46% $147.4M Benchmark Subject
DERM
Journey Medical Corporation
E 16/100 — 65.8% -19.5% -7.35% $145.9M /derm-vs-ngen →
PDSB
PDS Biotechnology Corporation
D 46/100 — — -35.0% -4.86% $151.2M /pdsb-vs-ngen →
CUE
Cue Biopharma Inc.
E 29/100 — — -35.0% -6.95% $151.6M /cue-vs-ngen →
MENS
Jyong Biotech Ltd.
E 33/100 — — -28.8% -0.53% $142.9M /mens-vs-ngen →

2. NGEN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

NervGen Pharma Corp. (NGEN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $147.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. NGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NervGen Pharma Corp. (NASDAQ: NGEN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.35 (-1.46% 1D, market cap $147.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, NGEN ranks #370 in composite RQD confidence.

How does NGEN compare to DERM and PDSB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NGEN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, DERM (Journey Medical Corporation) holds a E grade (16/100 RQD, P/E N/A, ROIC -19.5%, cap $145.9M) and PDSB (PDS Biotechnology Corporation) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M). Among the 5-stock peer group, NGEN leads on earnings multiple (N/A) while DERM leads on capital efficiency (-19.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NGEN?

For NervGen Pharma Corp. (NGEN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #370 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

NGEN last traded at $1.35 (-1.46% on volume of 561,074 shares), positioning the stock -27.81% below its 50-day simple moving average ($1.87) and -51.79% below its 200-day simple moving average ($2.80). Across its 52-week range of $1.35 to $6.30, NGEN sits at the 0.0% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.18 to $1.52).

Direct Sub-Reports: NGEN RQD Cockpit NGEN 12M Forecast NGEN Earnings & Move NGEN Dividends & DRIP NGEN Insiders & 13F NGEN Whale Options NGEN Profit Sankey NGEN News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

NGEN — NervGen Pharma Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

NervGen Pharma Corp. (NGEN) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.35 (-1.46% 1D, market capitalization $147.4M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sector: Health Care. Industry: Biotechnology: Pharmaceutical Preparations. Exchange: NASDAQ.. Is a NASDAQ-listed Health Care issuer in Biotechnology: Pharmaceutical Preparations. Products, customers, and revenue model are not described in source data.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.35 – $6.30 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is Health Care / Biotechnology: Pharmaceutical Preparations, which is not sufficient to map ripple effects.

  • Key Question #1: Can NGEN sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $6.30 52-week high?
  • Key Question #3: How sensitive is NGEN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NervGen Pharma Corp. (NGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NGEN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NGEN Bull vs. Bear Conversation Board — What's Your Call at $1.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NGEN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NGEN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1.73 (+26.3%)
📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest component of the rating, and

Long NGEN at $1.37 targeting $1.73. The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is the strongest component of the rating, and the company has begun a pivotal Phase 3 trial of NVG-291.. Institutional whale score is 3/20 and the risk/reward vs. the $1.35 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@ForensicBear Shorting a 3/20 institutional whale-flow stock at $1.37 is dangerous when funds are rotating into Health Care.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.15 (-16.1%)
Spot @ $1.37

The RQD rating is a D with ROIC at 0%, FCF yield at 0%, and Whale Flow scored only 5/20, while the news feed carries a RED risk-watch i

Sitting on the sidelines or leaning short NGEN above $1.37. The RQD rating is a D with ROIC at 0%, FCF yield at 0%, and Whale Flow scored only 5/20, while the news feed carries a RED risk-watch item on a -5.33% session drop.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $6.30.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%